Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is an orally active, direct-acting, reversible P2Y12 platelet inhibitor.
## Primary Indications
* Reduction of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
* Prevention of stent thrombosis in patients treated with a coronary stent.
## Adult Dosing
* **ACS:** Loading dose of 180 mg orally once, followed by 90 mg orally twice daily.
* **Post-MI ( $\ge$ 1 year duration):** 60 mg orally twice daily.
* **Stent Thrombosis Prevention:** Typically initiated as per ACS guidelines.
The duration of therapy is individualized based on patient risk factors and clinical events. Standard durations are often 12 months for ACS, but may be extended. For post-MI patients, therapy may be continued long-term. Consult local guidelines for specific duration recommendations.
## Pediatric Dosing
Ticagrelor is not recommended for use in pediatric patients due to lack of data.
## Dose Adjustments
No dose adjustments are necessary for hepatic or renal impairment. However, caution is advised in patients with severe hepatic impairment.
## Contraindications
* Active pathological bleeding.
* History of transient ischemic attack (TIA) or stroke.
* Known hypersensitivity to ticagrelor or any component of the formulation.
## Adverse Effects
* **Common:** Dyspnea, bleeding (major and minor, including intracranial and fatal), bradycardia.
* **Serious:** Life-threatening bleeding, ventricular pauses.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase ticagrelor exposure. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may decrease ticagrelor exposure.
* **CYP3A4 Substrates:** Ticagrelor can inhibit CYP3A4, increasing plasma concentrations of substrates (e.g., simvastatin, atorvastatin). Higher doses of statins may be needed.
* **Aspirin:** Concomitant use with aspirin is generally recommended for ACS patients but increases bleeding risk. The optimal dose of aspirin in conjunction with ticagrelor is debated; low-dose aspirin ( $\le$ 100 mg daily) is often preferred.
* **Other Antiplatelets/Anticoagulants:** Increased risk of bleeding.
## Monitoring
* **Bleeding:** Closely monitor for signs and symptoms of bleeding.
* **Cardiac Function:** Monitor for bradycardia.
* **Renal Function:** Baseline and periodic assessment.
* **Hepatic Function:** Baseline and periodic assessment, especially in patients with moderate hepatic impairment.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, unlike clopidogrel, which is irreversible. This may offer advantages in situations requiring platelet function restoration.
* Dyspnea is a common side effect and is usually mild and transient. If severe or persistent, it may warrant discontinuation.
* Ticagrelor is a potent antiplatelet agent. Discontinuation should be carefully considered due to the increased risk of thrombotic events. If interruption is necessary, the shortest possible duration should be aimed for.
* The maintenance dose of 60 mg twice daily is indicated for patients $\ge$ 1 year post-MI or those continuing long-term therapy after ACS.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the official prescribing information and current clinical guidelines for definitive guidance.
